Instead of passively waiting for clarity, Almac aggregated common sponsor concerns about new UK trial regulations and presented them to the MHRA. This proactive engagement was "unprecedented" and resulted in the regulator rapidly updating its guidance, demonstrating that a collaborative approach can shape and accelerate regulatory clarification.
Unlike main investigational drugs (IMPs), non-investigational medicinal products (NIMPs), such as rescue medications, have no transitional arrangements under new UK regulations. Sponsors must immediately relabel existing NIMP stock or file for a substantial amendment, a critical detail that could jeopardize ongoing trials.
Products from the same manufacturing batch face different UK compliance rules depending on their import date. Kits imported and certified before the deadline are fine, but kits from the same batch imported after the deadline must comply with new labeling rules, creating a significant risk for sponsors managing global inventory.
The UK's MHRA implemented significant clinical trial reforms in just one year, signaling its intent to operate with speed and attract more trials post-Brexit. This rapid pace is not just logistical; it's a deliberate message to the global pharmaceutical industry about the UK's new, more nimble regulatory environment.